Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 1
1979 1
1990 1
1992 1
1994 1
1996 3
1997 10
1998 2
1999 6
2000 5
2001 8
2002 5
2003 9
2004 4
2005 5
2006 2
2007 1
2008 8
2009 3
2010 11
2011 10
2012 13
2013 10
2014 10
2015 12
2016 21
2017 19
2018 33
2019 36
2020 24
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 19047254

239 results
Results by year
Filters applied: . Clear all
Page 1
Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
Strouse JJ, Lanzkron S, Beach MC, Haywood C, Park H, Witkop C, Wilson RF, Bass EB, Segal JB. Strouse JJ, et al. Pediatrics. 2008 Dec;122(6):1332-42. doi: 10.1542/peds.2008-0441. Pediatrics. 2008. PMID: 19047254 Review.
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB. Lanzkron S, et al. Ann Intern Med. 2008 Jun 17;148(12):939-55. doi: 10.7326/0003-4819-148-12-200806170-00221. Epub 2008 May 5. Ann Intern Med. 2008. PMID: 18458272 Free PMC article. Review.
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
Kinney TR, Helms RW, O'Branski EE, Ohene-Frempong K, Wang W, Daeschner C, Vichinsky E, Redding-Lallinger R, Gee B, Platt OS, Ware RE. Kinney TR, et al. Blood. 1999 Sep 1;94(5):1550-4. Blood. 1999. PMID: 10477679 Clinical Trial.
Hydroxyurea for the treatment of sickle cell disease.
Segal JB, Strouse JJ, Beach MC, Haywood C, Witkop C, Park H, Wilson RF, Bass EB, Lanzkron S. Segal JB, et al. Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Evid Rep Technol Assess (Full Rep). 2008. PMID: 18457478 Free PMC article. Review.
When should hydroxyurea be used for children with sickle cell disease?
Mueller BU. Mueller BU. Pediatrics. 2008 Dec;122(6):1365-6. doi: 10.1542/peds.2008-1058. Pediatrics. 2008. PMID: 19047256 No abstract available.
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.
Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Zimmerman SA, et al. Blood. 2004 Mar 15;103(6):2039-45. doi: 10.1182/blood-2003-07-2475. Epub 2003 Nov 20. Blood. 2004. PMID: 14630791 Clinical Trial.
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE. John CC, et al. N Engl J Med. 2020 Jun 25;382(26):2524-2533. doi: 10.1056/NEJMoa2000146. N Engl J Med. 2020. PMID: 32579813 Clinical Trial.
Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ. Scott JP, et al. J Pediatr. 1996 Jun;128(6):820-8. doi: 10.1016/s0022-3476(96)70335-9. J Pediatr. 1996. PMID: 8648542
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE; REACH Investigators. Tshilolo L, et al. N Engl J Med. 2019 Jan 10;380(2):121-131. doi: 10.1056/NEJMoa1813598. Epub 2018 Dec 1. N Engl J Med. 2019. PMID: 30501550 Free PMC article. Clinical Trial.
Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
Luchtman-Jones L, Pressel S, Hilliard L, Brown RC, Smith MG, Thompson AA, Lee MT, Rothman J, Rogers ZR, Owen W, Imran H, Thornburg C, Kwiatkowski JL, Aygun B, Nelson S, Roberts C, Gauger C, Piccone C, Kalfa T, Alvarez O, Hassell K, Davis BR, Ware RE. Luchtman-Jones L, et al. Am J Hematol. 2016 Feb;91(2):238-42. doi: 10.1002/ajh.24255. Am J Hematol. 2016. PMID: 26615793 Free article.
239 results
Jump to page
Feedback